These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10947537)

  • 1. Findings of a three-year retrospective study to investigate prevalence and incidence of urinary incontinence and overactive bladder in a typical managed care setting.
    Day PL
    Pharm Pract Manag Q; 2000 Apr; 20(1):1-11. PubMed ID: 10947537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The economic impact of overactive bladder syndrome in six Western countries.
    Irwin DE; Mungapen L; Milsom I; Kopp Z; Reeves P; Kelleher C
    BJU Int; 2009 Jan; 103(2):202-9. PubMed ID: 19278532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and resources associated with the treatment of overactive bladder using retrospective medical care claims data.
    Hall JA; Nelson MA; Meyer JW; Williamson T; Wagner S
    Manag Care Interface; 2001 Aug; 14(8):69-75. PubMed ID: 11517841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of medication adherence and associated health care costs in an older population with overactive bladder syndrome: a longitudinal cohort study.
    Balkrishnan R; Bhosle MJ; Camacho FT; Anderson RT
    J Urol; 2006 Mar; 175(3 Pt 1):1067-71; discussion 1071-2. PubMed ID: 16469620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and burden of overactive bladder in the United States.
    Stewart WF; Van Rooyen JB; Cundiff GW; Abrams P; Herzog AR; Corey R; Hunt TL; Wein AJ
    World J Urol; 2003 May; 20(6):327-36. PubMed ID: 12811491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates.
    Nitz NM; Jumadilova Z; Darkow T; Frytak JR; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S130-9. PubMed ID: 16161386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower urinary tract symptoms in women.
    Milsom I
    Curr Opin Urol; 2009 Jul; 19(4):337-41. PubMed ID: 19444118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs of urinary incontinence and overactive bladder in the United States: a comparative study.
    Hu TW; Wagner TH; Bentkover JD; Leblanc K; Zhou SZ; Hunt T
    Urology; 2004 Mar; 63(3):461-5. PubMed ID: 15028438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A longitudinal population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in women.
    Wennberg AL; Molander U; Fall M; Edlund C; Peeker R; Milsom I
    Eur Urol; 2009 Apr; 55(4):783-91. PubMed ID: 19157689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining overactive bladder: epidemiology and burden of disease.
    Tubaro A
    Urology; 2004 Dec; 64(6 Suppl 1):2-6. PubMed ID: 15621220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related consequences of overactive bladder.
    Wagner TH; Hu TW; Bentkover J; LeBlanc K; Stewart W; Corey R; Zhou Z; Hunt T
    Am J Manag Care; 2002 Dec; 8(19 Suppl):S598-607. PubMed ID: 12516954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overactive bladder: prevalence, risk factors and relation to stress incontinence in middle-aged women.
    Teleman PM; Lidfeldt J; Nerbrand C; Samsioe G; Mattiasson A;
    BJOG; 2004 Jun; 111(6):600-4. PubMed ID: 15198789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of overactive bladder and urinary incontinence.
    Parazzini F; Lavezzari M; Arbitani W
    J Fam Pract; 2002 Dec; 51(12):1072-5. PubMed ID: 12540334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overactive bladder: an update.
    Hashim H; Abrams P
    Curr Opin Urol; 2007 Jul; 17(4):231-6. PubMed ID: 17558264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for stress, urge or mixed urinary incontinence in Italy.
    Parazzini F; Chiaffarino F; Lavezzari M; Giambanco V;
    BJOG; 2003 Oct; 110(10):927-33. PubMed ID: 14550363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
    Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
    Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence of urinary incontinence.
    Milsom I
    Acta Obstet Gynecol Scand; 2000 Dec; 79(12):1056-9. PubMed ID: 11130087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of urinary incontinence in Medicare managed care beneficiaries: results from the 2004 Medicare Health Outcomes Survey.
    Mardon RE; Halim S; Pawlson LG; Haffer SC
    Arch Intern Med; 2006 May; 166(10):1128-33. PubMed ID: 16717176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence, awareness and determinants of health care-seeking behaviour for urinary incontinence in Qatari women: a neglected problem?
    Saleh N; Bener A; Khenyab N; Al-Mansori Z; Al Muraikhi A
    Maturitas; 2005 Jan; 50(1):58-65. PubMed ID: 15590215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetes--prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany.
    Stock SA; Redaelli M; Wendland G; Civello D; Lauterbach KW
    Diabet Med; 2006 Mar; 23(3):299-305. PubMed ID: 16492214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.